ASN
STRO icon

Advisory Services Network’s Sutro Biopharma STRO Stock Holding History

Advisory Services Network’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15
Closed -$374 – 4328
2026
Q1 		$374 Buy
+15
New +$271 ﹤0.01% 4470
2025
Q4 		– Sell
-15
Closed -$128 – 3961
2025
Q3 		$128 Buy
+15
New +$128 ﹤0.01% 4292

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Advisory Services Network's STRO Position: Q2 2026 in Review

Advisory Services Network sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 15 shares — an estimated $374 sold.

Advisory Services Network first reported a position in STRO in Q3 2025 and held it in 2 quarters. The position peaked at $374 in Q1 2026. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Advisory Services Network reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
  • Advisory Services Network sold 15 Sutro Biopharma shares in Q2 2026, an estimated $374.
  • Advisory Services Network first reported a position in Sutro Biopharma in Q3 2025 and held it in 2 quarters.
  • Advisory Services Network's Sutro Biopharma position peaked at $374 in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.